Navigation Links
Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
Date:9/19/2008

From Neurons to Beyond; Advancing the Frontiers of Life Science Research Toward Realizing Healthcare Solutions in Areas of Clinical Need Such as Parkinson's, Alzheimer's, and Autism

BOSTON, Sept. 19 /PRNewswire/ -- Neurosilicon (http://www.neurosilicon.com) has announced the availability of their innovative Photoconductive Stimulation Device (PSD). The PSD allows researchers to induce rapid, non-invasive activation of excitable cells, such as neurons. This novel research innovation will enable researchers to significantly expand the depth, breadth, and complexity of experimental research approaches aimed at understanding and addressing areas of unmet healthcare need such as in Parkinson's disease, Alzheimer's, and Autism. The PSD makes use of a property called the Photoconductive Stimulation Effect (PSE). This novel device is based on the PSE principle that states when visible light strikes silicon in combination with a specific current, a local field potential (LFP) is generated. This LFP can be harnessed to initiate depolarization in excitable cells without causing any damage to the cell. Further, the PSD induced depolarization can be applied at user-definable frequency, intensity, and duration, further extending experimental variation, design, and control. Taken together, the PSD will enable laboratory researchers and industry technicians to depolarize excitable cells in a highly targeted and readily reproducible manner significantly extending the breadth and depth of experimental protocols, as well as enabling high throughput testing, sample screening, and drug discovery.

This technology provides researchers with the means to dynamically study excitation dependent cellular responses without the requirement for a direct physical link to the cell (such as with electrodes used for patch clamping or transistor contact necessary for use with micro electrode arrays). The non-invasive, optical targeting used by the PSD allows for an extended observation period, dependent only upon the environmental support available for the cells. Further, non-invasive electrical stimulation can be done without causing damage to the cells while optical targeting enables highly controlled depolarization of only target cells. The PSD can also be used in place of pharmacological agonist stimulation, which does not allow for specific cell targeting and/or rapid repetitive depolarization, where such experimental capabilities would be desirable.

The PSD system controller is a fully contained, easy to use electronics base that readily fits into any bench-top environment. Cells for experimentation are grown on the silicon PSD substrates that fit in industry standard 24 well plates for cell culture and storage, and are then mounted onto the reusable PSD experimental chamber for live cell observation using any standard up-right microscope. Current promotion bundles including the PSD controller, experimental chambers, and cell culture substrates begin at $3,550.00.

Advancing the frontiers of excitable cell research, such as in neurons and muscle cells will serve to further our understanding of the mechanisms underlying cellular structure/function relationships. Additionally, it will enable scientists to better elucidate how these mechanisms go awry during disease states and potentially how to better address (and/or prevent) the disease state (and/or injury) following onset. Further, the diagnostic testing and drug discovery potential of the PSD will provide insights into the identification and development of new therapeutics.

About Neurosilicon

Neurosilicon develops novel brain-computing interfaces to expand the scientific understanding of the human brain and to revolutionize and improve the effectiveness of drug discovery. The company's flagship product, the Photoconductive Stimulation Device (PSD) stimulates excitable cells in a precise and controllable fashion. Neurosilicon is comprised of a multidisciplinary team of neuroscientists and engineers. Together this team has spent three years developing, testing, and optimizing their novel photoconductive stimulation technology, significantly advancing the boundaries of life science research.

For more information on the Photoconductive Stimulation Device (PSD), or to order, please visit http://www.neurosilicon.com.


'/>"/>
SOURCE Neurosilicon
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
2. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
3. Novel Compound Shows Promise for Treatment of Alcoholism
4. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
5. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
6. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
7. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
10. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):